Publications by authors named "Mie Inao"

Claim this Profile
A
A case of non-HIV pneumocystis pneumonia in a patient with cirrhosis-associated immune dysfunction.
Kai Miyamoto, Yoshihito Uchida, Shohei Tsuji, Mie Inao, Kayoko Sugawara

Clin J Gastroenterol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, feasibility, and acceptability of physiotherapy combined with strength training using active video games for older patients with musculoskeletal conditions.
Keiichi Takei, Shinpei Morita, Yoshinobu Watanabe, Miho Suganami, Mie Inao

Disabil Rehabil Assist Technol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Machine learning in primary biliary cholangitis: A novel approach for risk stratification.
Alessio Gerussi, Damiano Verda, Davide Paolo Bernasconi, Marco Carbone, Atsumasa Komori, Mie Inao

Liver Int· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Furosemide as a factor to deteriorate therapeutic efficacy of tolvaptan in patients with decompensated cirrhosis.
Yoshihito Uchida, Mie Inao, Shohei Tsuji, Hayato Uemura, Jun-Ichi Kouyama

Hepatol Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Furosemide as a factor to deteriorate therapeutic efficacy of rifaximin in patients with decompensated cirrhosis.
Yoshihito Uchida, Shohei Tsuji, Hayato Uemura, Jun-Ichi Kouyama, Kayoko Naiki, Mie Inao

Hepatol Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A validation study of the Ursodeoxycholic Acid Response Score in Japanese patients with primary biliary cholangitis.
Minami Yagi, Kosuke Matsumoto, Atsumasa Komori, Masanori Abe, Naoaki Hashimoto, Mie Inao

Liver Int· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bezafibrate Improves GLOBE and UK-PBC Scores and Long-Term Outcomes in Patients With Primary Biliary Cholangitis.
Akira Honda, Atsushi Tanaka, Tetsuji Kaneko, Atsumasa Komori, Masanori Abe, Mie Inao

Hepatology· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
Yoshihito Uchida, Kayoko Naiki, Jun-Ichi Kouyama, Kayoko Sugawara, Masamitsu Nakao, Mie Inao

PLoS One· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis.
Yoshihito Uchida, Shugo Nakamura, Jun-Ichi Kouyama, Kayoko Naiki, Daisuke Motoya, Mie Inao

Sci Rep· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retreatment with sofosbuvir/ledipasvir with or without lead-in interferon-β injections in patients infected with genotype 1b hepatitis C virus after unsuccessful daclatasvir/asunaprevir therapy.
Hayato Uemura, Yoshihito Uchida, Jun-Ichi Kouyama, Kayoko Naiki, Shinpei Yamaba, Mie Inao

Hepatol Res· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic hepatitis caused by hepatitis C virus showing a discrepancy between serogroup and genotype because of intergenotypic 2b/1b recombination: A pitfall in antiviral therapy with direct-acting antivirals.
Hayato Kurata, Yoshihito Uchida, Jun-Ichi Kouyama, Kayoko Naiki, Manabu Nakazawa, Mie Inao

Hepatol Res· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
"
"Reversi-type virologic failure" involved in the development of non-structural protein 5A resistance-associated variants (RAVs) in patients with genotype 1b hepatitis C carrying no signature RAVs at baseline.
Yoshihito Uchida, Jun-Ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Mie Inao

Hepatol Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential therapy consisting of glucocorticoid infusions followed by granulocyte-monocyte absorptive apheresis in patients with severe alcoholic hepatitis.
Kazuhiro Watanabe, Yoshihito Uchida, Kayoko Sugawara, Kayoko Naiki, Mie Inao

J Gastroenterol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of rare resistance-associated variants that are extremely tolerant against NS5A inhibitors during daclatasvir/asunaprevir therapy by a two-hit mechanism.
Yoshihito Uchida, Jun-Ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Mie Inao

Hepatol Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Alcohol Consumption on Hepatocarcinogenesis in Japanese Patients With Fatty Liver Disease.
Yusuke Kawamura, Yasuji Arase, Kenji Ikeda, Norio Akuta, Masahiro Kobayashi, Mie Inao

Clin Gastroenterol Hepatol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing.
Yoshihito Uchida, Jun-Ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Satsuki Ando, Mie Inao

J Gastroenterol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter prospective study to optimize the efficacy of triple therapy with telaprevir in patients with genotype 1b hepatitis C virus infection according to an algorithm based on the drug Adherence, IL-28B Gene Allele and Viral Response Trial (AG & RGT).
Kayoko Sugawara, Youhei Koushima, Mie Inao, Nobuaki Nakayama, Sumiko Nagoshi

Hepatol Res· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C.
Yoshie Omori-Mizuno, Nobuaki Nakayama, Mie Inao, Junji Funyu, Shinichi Asabe

J Gastroenterol Hepatol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcatheter arterial chemoembolization for hepatocellular carcinoma: Comparison of the therapeutic efficacies between miriplatin and epirubicin.
Takahiro Handa, Yukinori Imai, Kayoko Sugawara, Taku Chikayama, Manabu Nakazawa, Mie Inao

Hepatol Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel hepatitis B virus strain developing due to recombination between genotypes H and B strains isolated from a Japanese patient.
Yoshihito Uchida, Jun-Ichi Kouyama, Kayoko Naiki, Kayoko Sugawara, Mie Inao

Hepatol Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic strategy for patients with bleeding rectal varices complicating liver cirrhosis.
Kiyoko Yoshino, Yukinori Imai, Manabu Nakazawa, Taku Chikayama, Satsuki Ando, Mie Inao

Hepatol Res· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Telaprevir-induced, but not pegylated interferon-associated, retinopathy as a noteworthy adverse effect during triple antiviral therapy in patients with chronic hepatitis C.
Kayoko Sugawara, Mie Inao, Nobuaki Nakayama, Satoshi Mochida

J Gastroenterol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retreatment with peginterferon α-2a + ribavirin in patients who failed previous peginterferon α-2b + ribavirin combination therapy.
Taisuke Ueda, Kaoru Tsuchiya, Satoru Hashimoto, Taisuke Inoue, Nobuyuki Enomoto, Mie Inao

Dig Dis· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SNPs in the promoter region of the osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV.
Kazuhiro Hamaoka, Sumiko Nagoshi, Kayoko Sugawara, Kayoko Naiki, Yoshihito Uchida, Mie Inao

Hepatol Int· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study.
Namiki Izumi, Yasuhiro Asahina, Masayuki Kurosaki, Gotaro Yamada, Tsutomu Kawai, Mie Inao

J Gastroenterol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis